Patients

Our technology

The ImmTAC® platform generates a new class of bi-specific biologics that is designed to overcome the limitations of other immuno-oncology agents by combining a T cell receptor (TCR)-targeting system with an anti-CD3 effector function to activate a highly potent and specific T cell response to cancer cells.
IMCgp100, our lead ImmTAC® molecule, specifically targets the melanoma-associated antigen gp100.

Read more

Disease indications

Oncology overview

Within oncology, we are applying our ImmTAC® platform to overcome the limitations of current anti-cancer therapies to deliver:

  • Potent and specific re-direction of a patient’s own T cells to kill the target cancer cells.
  • Access to a pool of antigenic targets that is up to nine-fold greater than traditional antibody-based therapies.

This unique and potent mechanism of action provided by ImmTAC® molecules gives the potential to tackle diverse tumour types, including solid tumours that are characteristically immune excluded, or "cold" and thus resistant to the majority of existing immunotherapies that target activation of pre-existing immune cells. ImmTAC® molecules have been shown to convert "cold" tumours to "hot" through their T cell redirecting activity.

Beyond IMCgp100, we are continuing to apply our ImmTAC® technology to target a diverse range of cancer indications.

Uveal Melanoma

Uveal melanoma is an aggressive form of melanoma that arises from melanocytes in the uveal tract of the eye. Survival in uveal melanoma has remained largely unchanged since the early 1970s with the greatest burden in metastatic disease. Currently, there is no proven standard of care for metastatic uveal melanoma, meanwhile various therapies, including checkpoint inhibitors, are used without definitive evidence of benefit in this patient population.

IMCgp100 is designed to specifically target the melanoma-associated antigen gp100 and engages T cells to direct a potent and specific response against the cancer cells.

Clinical trial locations

Europe

Europe

We have a number of clinical trials currently recruiting patients across Europe.

View all locations
North America

North America

We have a number of clinical trials currently recruiting patients across the US and Canada.

View all locations
Australasia

Australasia

We have a number of clinical trials currently recruiting patients across Australasia.

View all locations

Clinical trials information

We have a number of clinical trials currently recruiting patients

Trial A Pivotal Study Investigating The Safety And Efficacy Of IMCgp100 Versus Investigator Choice In Advanced Uveal Melanoma (NCT03070392)

Conditions

Uveal Melanoma

View details

Trial A Phase 1 Study Of The Intra-Patient Escalation Dosing Regimen With IMCgp100 In Patients With Advanced Uveal Melanoma (NCT02570308)

Conditions

Uveal Melanoma

View details

Trial A Phase 1b/2 Study Of The Combination Of IMCgp100 With Durvalumab And/Or Tremelimumab In Cutaneous Melanoma (NCT02535078)

Conditions

Malignant Melanoma

View details

Trial IMCgp100-401 Rollover Study Designed To Provide Continued Access To IMCgp100 For Eligible Patients With Advanced Melanoma Who Have Previously Participated In An IMCgp100Study (NCT02889861)

Conditions

Malignant Melanoma

View details

Trial Safety and Efficacy of IMCnyeso in Advanced NY-ESO-1 and/or LAGE-1A Positive Cancers (NCT03515551)

Conditions

Melanoma

Advanced NSCLC

Urothelial Carcinoma and Synovial Sarcoma

View details

Further Information

For more information on clinical trials see clinicaltrials.gov.

If you have additional questions, please send them to Patientinfo@immunocore.com.

If you are a medical professional and require further information about Immunocore, our clinical research or clinical trials, please send an email to medicalinformation@immunocore.com.

If you are a patient and seeking information about clinical trials, please send an email to Patientinfo@immunocore.com.

Patients are encouraged to contact their doctor ahead of contacting Immunocore including for questions regarding suitability or criteria for participating in a clinical trial or safety issues.

Pipeline products

Immunocore has a robust pipeline of wholly-owned and partnered programmes

Alongside high value proprietary programmes, Immunocore has co-discovery and co-development programmes with Lilly and discovery programmes, including milestones and royalties, with Genentech, GlaxoSmithKline and MedImmune (AstraZeneca).